pyrazines has been researched along with Lung Neoplasms in 199 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.01) | 18.7374 |
| 1990's | 12 (6.03) | 18.2507 |
| 2000's | 73 (36.68) | 29.6817 |
| 2010's | 85 (42.71) | 24.3611 |
| 2020's | 27 (13.57) | 2.80 |
| Authors | Studies |
|---|---|
| Bironzo, P; Bungaro, M; Capelletto, E; Denis, L; Koustenis, A; Novello, S | 1 |
| Castellano, GM; Garbuzenko, OB; Malhotra, J; Minko, T; Pine, SR; Sabaawy, HE; Zeeshan, S | 1 |
| Meiners, S; Meul, T; Schlesser, C; Stathopoulos, G | 1 |
| Liang, L; Ma, G; Wang, D; Xu, L; Xu, X | 1 |
| Chen, DS; Fang, Y; Gao, W; Gu, Y; Huang, R; Ma, P; Shu, Y; Wu, X; Zhang, HW | 1 |
| Abreu, RF; Carraro, DM; Cavalher, FP; Corassa, M; Costa, FD; de Lima, VCC; Freitas, HC; Oliveira, TB; Silva, TN; Torrezan, GT | 1 |
| Arthur, G; Bebb, DG; Bolyos, A; Bose, P; Goutam, S; Jette, NR; Lees-Miller, SP; Petersen, LF; Radhamani, S; Ye, R | 1 |
| Downward, J; Hancock, DC; Herbert, E; Horswell, S; Janes, MR; Li, LS; Molina-Arcas, M; Moore, C; Mugarza, E; Rana, S; Romero-Clavijo, P; van Maldegem, F | 1 |
| Anderton, MJ; Bethel, P; Breed, J; Cook, C; Davies, EJ; Dobson, A; Dong, Z; Fairley, G; Farrington, P; Feron, L; Flemington, V; Gibbons, FD; Graham, MA; Greenwood, R; Hanson, L; Hopcroft, P; Howells, R; Hudson, J; James, M; Jones, CD; Jones, CR; Lamont, S; Lewis, R; Li, Y; Lindsay, N; McCabe, J; McGuire, T; Rawlins, P; Roberts, K; Sandin, L; Simpson, I; Swallow, S; Tang, J; Tomkinson, G; Tonge, M; Wang, Z; Ward, RA; Zhai, B | 1 |
| Burns, TF; Camidge, DR; Cetnar, J; Gerber, DE; Horobin, JC; Jeong, W; Keegan, M; Kelly, RJ; Li, M; Morgensztern, D; Ramalingam, SS; Scaglioni, PP; Spigel, DR; Vaikus, L; Weaver, DT; Zhang, S | 1 |
| Früh, M; Peters, S; Schmid, S | 1 |
| Ahn, MJ; Cantarini, M; Cho, BC; Frewer, P; Han, JY; Kim, SW; Kowalski, D; Lee, JS; Mellemgaard, A; Orlov, S; Ottesen, L; Ou, X; Oxnard, G; Sequist, LV; Su, WC; Verheijen, RB; Yang, JC; Yu, H | 1 |
| Ahn, MJ; Frigault, MM; Ghiorghiu, D; Goto, K; Horn, L; Kim, SW; Mann, H; Ohe, Y; Oxnard, GR; Ramalingam, SS; Saka, H; Thress, KS; Vishwanathan, K; Yang, JC; Yu, H | 1 |
| Arai, S; Atagi, S; Fukuda, K; Han, X; Hanayama, R; Ishimura, A; Kaira, K; Kita, K; Matsumoto, I; Matsumoto, K; Nishiyama, A; Ohtsubo, K; Suzuki, T; Takayama, K; Takeuchi, S; Taniguchi, H; Taniguchi, Y; Tanimoto, A; Terashima, M; Uehara, H; Wang, R; Wang, W; Yamada, T; Yamano, T; Yamashita, K; Yano, S; Yoshimura, A | 1 |
| Ahmed, GF; Chang, JH; Chen, GY; Egile, C; Fang, J; Frigault, MM; Hartmaier, R; He, JX; Huang, JA; Li, W; Liu, XQ; Mellemgaard, A; Morgan, S; Shu, YQ; Verheijen, RB; Wu, YL; Yang, JJ; Yang, L; Yang, N; Zhou, C | 1 |
| Cai, T; Du, W; Fu, Y; Huang, JA; Lei, Z; Liu, T; Liu, Z; Wang, A; Zeng, Y; Zhang, Y; Zhu, J | 1 |
| Chahine, JJ; Chen, V; Giaccone, G; Iwama, E; Kallakury, B; Kim, IK; McCutcheon, JN; Petricoin, E; Pierobon, M; Umemura, S; Wang, C; Zhang, YW; Zhao, X | 1 |
| Adachi, J; Araki, M; Friboulet, L; Fujita, N; Katayama, K; Katayama, R; Kukimoto-Niino, M; Kutkowska, J; Ma, B; Maruyama, K; Mizuta, H; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sagae, Y; Sasakura, Y; Shirouzu, M; Simizu, S; Takagi, S; Takemoto, A; Tamai, K; Watanabe, K; Yanagitani, N | 1 |
| Branigan, TB; D'Andrea, AD; DeCaprio, JA; Deraska, P; Kozono, D; Reavis, HD; Rivas, HG; Sambel, L; Schade, AE; Shapiro, GI | 1 |
| Aladjem, MI; Beck, E; Ceribelli, M; Chen, L; Dahmen, H; Desai, P; Elenbaas, B; Figg, WD; Itkin, Z; Khan, J; Kim, S; Kindrick, JD; Klumpp-Thomas, C; Lee, MJ; Lee, S; McKnight, C; Michael, S; Nichols, S; Peer, CJ; Pommier, Y; Puc, J; Rajapakse, VN; Redon, CE; Schultz, CW; Sciuto, L; Shimellis, H; Steinberg, SM; Sun, Y; Takahashi, N; Thomas, A; Thomas, CJ; Travers, J; Trepel, JB; Varonin, J; Wei, JS; Wilson, KM; Yuno, A; Zenke, FT; Zhang, X; Zhang, Y; Zimmermann, A | 1 |
| Ali, A; Bassal, MA; Bassères, DS; Bizzarri, R; Branstrom, A; Bueno, R; Castaño, J; Ciampi, R; Clohessy, JG; Crucitta, S; Csizmadia, E; Danesi, R; De Rienzo, A; Del Re, M; Fhu, CW; Fox, S; Giorgetti, A; Gustafson, CE; Klein, AM; Kocher, O; Krishnan, I; Levantini, E; Levy, RD; Li, J; Magli, MC; Maroni, G; Maymi, VA; Meyerovitz, CV; Pandell, N; Panella, R; Savova, V; Storti, B; Tenen, DG; Tramontozzi, PJ; Vermilya, K; Weetall, M; Welner, RS; Yang, H; Zhang, J; Zilionis, R | 1 |
| Ahmed, GF; Hayama, M; Hida, T; Hirashima, T; Kurata, T; Mellemgaard, A; Ohe, Y; Ou, X; Oxnard, GR; Saka, H; Sugibayashi, K; Verheijen, RB; Yoh, K | 1 |
| Elloumi, F; Jo, U; Kim, SH; Murai, Y; Pommier, Y; Rajapakse, VN; Saha, LK; Schultz, CW; Senatorov, IS; Takahashi, N; Thomas, A; Zenke, FT; Zimmermann, A | 1 |
| Ikeda, Y; Nakayama, Y; Saito, Y; Yasutake, R; Yuki, R | 1 |
| Cao, L; Chen, G; Chen, Y; Cheng, Y; Fan, Y; Fang, J; Guo, Q; Han, Z; Jiang, L; Li, J; Li, X; Liang, Z; Lu, S; Luo, X; Ma, R; Ren, Y; Shi, J; Su, W; Sun, S; Wang, L; Xu, H; Yang, N; Zhang, H; Zhou, J | 1 |
| Alkan, F; Altelaar, M; Barrera, A; Beijersbergen, R; Buijs, M; Chalkiadakis, T; de Visser, KE; de Wit, E; Debets, DO; Faller, W; Győrffy, B; Hoekman, L; Huber, A; Jonkers, J; Lieftink, C; Manjón, AG; Mayayo-Peralta, I; Medema, R; Monkhorst, K; Morris, B; Prekovic, S; Reddy, T; Schuurman, K; Severson, T; Silva, J; Teunissen, H; van den Broek, B; Wellenstein, MD; Yavuz, S; Zwart, W | 1 |
| Abel, L; Baschnagel, AM; Clark, PA; Elnaggar, JH; Kaushik, S; Kimple, RJ; Kromke, AC; Leal, TA; Longhurst, CA; Nickel, KP; Skiba, JH; VanBeek, HJ; Zhao, SG | 1 |
| Dawar, R; Drusbosky, LM; Ikpeazu, CV; Rodriguez, E | 1 |
| Markham, A | 1 |
| Bai, R; Chen, N; Fan, Y; Hao, LJ; Hao, Y; Li, GS; Liu, YJ; Mao, Y; Shi, C; Wang, YJ; Xia, GX; Yu, JX; Zhang, CC; Zhang, J; Zhang, LD; Zhao, F | 1 |
| Byers, LA; Cristea, S; Fan, YH; Gibbons, DL; Glisson, BS; Heymach, JV; Li, L; Minna, JD; Piwnica-Worms, H; Redwood, AB; Sage, J; Sen, T; Shames, DS; Stewart, CA; Tong, P; Valliani, A; Wang, J | 1 |
| Ahmed, S; Blackhall, F; Chen, J; Ciuleanu, TE; Kim, JH; Mezger, J; Park, K; Poondru, S; Thomas, M; VanTornout, JM; Whitcomb, D | 1 |
| Beleggia, F; Büttner, R; Doerr, F; George, J; Hermann, S; Persigehl, T; Rehkämper, T; Reinhardt, HC; Schmitt, A; Thomas, RK; Walter, V; Weber, JP; Wittersheim, M | 1 |
| Batra, SK; Dhanasingh, I; Kanteti, R; Kaushik, G; Kindler, HL; Kulkarni, P; Mambetsariev, B; Mirzapoiazova, T; Nasser, MW; Ponnusamy, MP; Riehm, JJ; Salgia, R; Seshacharyulu, P; Wang, J | 1 |
| Huang, HH; Liu, FB; Ruan, Z; Su, YJ; Wang, J; Zheng, J | 1 |
| Asahina, S; Azuma, K; Fukuoka, M; Hayashi, H; Hida, T; Ikeda, S; Inoue, A; Iwamoto, Y; Kiura, K; Komatsu, K; Morita, S; Nakagawa, K; Nakagawa, T; Nishio, M; Satouchi, M; Sugawara, S; Takeda, K | 1 |
| Alcoser, SY; Aziz, A; Borgel, S; Bottaro, DP; Colantonio, S; Dieckman, L; Doroshow, JH; Hiltke, T; Hollingshead, MG; Kaczmarczyk, J; Kinders, RJ; Lee, YH; Navas, T; Parchment, RE; Pfister, TD; Saul, RG; Takebe, N; Tomaszewski, JE; Whiteley, G | 1 |
| Akazawa, R; Azuma, K; Fukuoka, M; Hayashi, H; Inoue, A; Kaneko, Y; Kang, JH; Kim, SW; Kiura, K; Morita, S; Murakami, H; Nakagawa, K; Nakagawa, T; Nishio, M; Nokihara, H; Park, K; Seto, T; Shimazaki, M; Takeda, K; Tsai, CM; Yang, JC | 1 |
| Chung, A; Guimaraes, PPG; Jacks, T; Langer, R; Mitchell, MJ; Oberli, M; Riley, RS; Spektor, R; Tammela, T; Tan, M; Viana, CTR; Wang, K; Wu, K | 1 |
| De Koning, L; De Wolf, J; Jaurand, MC; Jean, D; Le Pimpec-Barthes, F; Meiller, C; Montagne, F; Quetel, L; Tranchant, R; Zucman-Rossi, J | 1 |
| Benes, CH; Borgmann, K; Dinkelborg, PH; Gheorghiu, L; Gurski, JM; Hong, TS; Jimenez, RB; Juric, D; Wang, M; Willers, H | 1 |
| Dhillon, S | 1 |
| Aerts, JGJV; Baas, P; Cedrés, S; Fennell, DA; Gilligan, D; Kindler, H; Nakano, T; Nolan, L; Nowak, AK; Pachter, JA; Pavlakis, N; Scherpereel, A; Taylor, P; van Meerbeeck, JP; Weaver, DT | 1 |
| Aben, N; Avelar, AT; Berns, A; Cozijnsen, M; de Vries, H; Nagel, R; Proost, N; van de Ven, M; van der Vliet, J; Wessels, LFA | 1 |
| Horn, L; Jie, F; Kelly, RJ; Krivoshik, A; Shepherd, FA | 1 |
| Hirano, M; Kaneko, N; Konagai, S; Koshio, H; Kuromitsu, S; Matsuya, T; Mori, M; Sakagami, H; Takeuchi, M; Tanaka, H; Yamamoto, H; Yamanaka, Y; Yuri, M | 1 |
| Afjei, R; Citterio, D; Hiruta, Y; Iwasawa, N; Kim, SB; Nakajima, T; Natarajan, A; Nishihara, R; Nishiyama, S; Paulmurugan, R; Sato, M; Suzuki, K; Yamamoto, E | 1 |
| Andreu, AL; Barreiro, E; de Kier Joffé, ED; Fermoselle, C; García-Arumí, E; Puente-Maestu, L; Puig-Vilanova, E; Tejedor, A; Urtreger, AJ | 1 |
| Ahuja, HG; Blank, JH; Campbell, TC; Hernan, HR; Hoang, T; Huie, MS; Johnson, PH; Kim, K; Kirschling, RJ; Kolesar, JM; Larson, MM; Oettel, KR; Robinson, EG; Traynor, AM; Wims, ME; Zhang, C | 1 |
| Eisner, F; Gerger, A; Pichler, M; Samonigg, H; Schaberl-Moser, R | 1 |
| Chen, SS; Falchook, G; Fok, JY; Fu, S; Heymach, J; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Stephen, B; Tsimberidou, AM; Wheler, J | 1 |
| Dobra, K; Hjerpe, A; Mundt, F; Nilsonne, G; Souri, P; Szulkin, A; Wasik, AM | 1 |
| Chen, CC; Cron, KR; D'Andrea, AD; Hsieh, G; Kozono, D; Kushwaha, DS; Merzon, D; Rameseder, J; Zhu, K | 1 |
| Baska, F; Breza, N; Kékesi, L; Kéri, G; Németh, G; Őrfi, L; Pató, J; Sipos, A | 1 |
| An, M; Hu, J; Hu, R; Li, X; Ruan, K; Shen, J; Song, G; Wu, N | 1 |
| Karthik, S; Ravikumar, V; Sankar, R; Varunkumar, K | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Barreiro, E; Chacon-Cabrera, A; de Kier Joffé, ED; Diament, MJ; Fermoselle, C; Mateu-Jimenez, M; Sandri, M; Urtreger, AJ | 1 |
| Ambudkar, SV; Ashby, CR; Bates, SE; Chen, ZS; Fu, LW; Kathawala, RJ; Patel, A; Robey, RW; Shukla, S; Talele, TT; Wang, YJ; Zhang, H; Zhang, YK | 1 |
| Alì, G; Bellelli, R; Castellone, MD; Fontanini, G; Gutkind, JS; Laukkanen, MO; Santoro, M; Teramoto, H | 1 |
| Cui, YJ; Fei, HR; Li, ZM; Sun, BL; Sun, YK; Wang, FZ; Wang, XY; Yang, XY; Zhang, JG | 1 |
| Drucker, L; Gottfried, M; Zismanov, V | 1 |
| Adjei, AA; Aubry, MC; Bearden, JD; Foster, NR; Johnson, DB; Mandrekar, SJ; Mattar, BI; Meyers, JP; Molina, JR; Northfelt, DW; Rowland, KM; Schild, SE; Thomas, SP; Zhao, Y | 1 |
| Lin, YL; Liu, M; Poo, WK | 1 |
| Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ | 1 |
| Anusha, C; Karthik, S; Ravikumar, V; Sankar, R; Varunkumar, K | 1 |
| Cho, J; Jang, HJ; Lee, HJ; Lee, HY; Lee, JJ; Lee, JS; Liu, D; Min, HY; Oh, SH; Park, SH; Wistuba, II; Yun, HJ | 1 |
| James, M; Jeong, JH; Lee, Y; Wang, Y; You, M | 1 |
| Aherne, GW; Box, G; Boxall, KJ; Collins, I; De Haven Brandon, AK; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Henley, AT; Hunter, JE; Lainchbury, M; Matthews, TP; McHardy, T; Osborne, J; Perkins, ND; Raynaud, FI; Reader, JC; Swales, K; Tall, M; Valenti, MR; Walton, MI | 1 |
| Barda, D; Barnard, D; Beckmann, R; Burke, T; Diaz, HB; Donoho, G; Jones, B; King, C; Marshall, M | 1 |
| Eckhardt, SG; Gadgeel, SM; Gedrich, R; Gogov, S; Juergens, RA; Macaulay, VM; McCarthy, S; Middleton, MR; Poondru, S; Rudin, CM; Stephens, AW | 1 |
| Ai, Y; Ding, K; Huang, Z; Kang, F; Lai, Y; Li, J; Peng, S; Ren, C; Tian, J; Zhang, Y; Zhu, B | 1 |
| Chen, S; Fu, Y; Jia, Y; Jiao, S; Wang, Z; Zang, A | 1 |
| Bach, S; Bazin, MA; Evenou, P; Marchand, P; Marhadour, S; Piessard, S; Roussakis, C; Rousseau, B; Ruchaud, S; Tomasoni, C; Vaisberg, AJ | 1 |
| Chao, B; Gao, AH; He, QJ; Hu, YH; Li, J; Ma, YM; Peng, YM; Zhou, YB; Zhu, QH | 1 |
| Boyd, TE; Hynes, SM; Kang, JH; Kim, SW; Lin, AB; Lin, J; Myrand, SP; Novello, S; Park, K; Pinder-Schenck, M; Richards, DA; Rosenberg, R; Scagliotti, G; Smith, D; Smyth, EN; Su, WC; Wijayawardana, S | 1 |
| Liang, Y; Lin, Y; Liu, Y; Yin, W; Zhang, J | 1 |
| Adam, A; Barry, ER; Beran, G; Castriotta, L; Clark, E; D'Cruz, CM; Henry, RE; Ladd, B; Markovets, A; Qing, W; Reimer, C; Ren, Y; Schuller, AG; Su, W; Zhou, F; Zinda, M | 1 |
| Ahn, MJ; Arpornwirat, W; Bazhenova, L; Chen, J; Chiappori, AA; Chow, LQ; de Lima, LG; Dechaphunkul, A; Eaton, K; Gadgeel, SM; Juergens, RA; Leighl, NB; Medley, S; Poondru, S; Rizvi, NA; Rudin, CM; Singh, M; Steinberg, J; Sunpaweravong, P | 1 |
| Kim, KW; Lu, B; Moretti, L | 1 |
| Bush, D; Carew, JS; Casero, RA; Cleveland, JL; Goodwin, A; Houghton, JA; Marton, LJ; Nawrocki, ST; Reddy, VK; Rehg, JE | 1 |
| Kasaoka, T; Nakajima, M; Nishiyama, H; Okada, M | 1 |
| Avendaño, C; Cuesta, Ede L; González, JF; Manguan-García, C; Ortín, I; Perona, R | 1 |
| Liu, X; Miao, JY; Pan, XH; Shin, DS; Xie, YS; Zhang, SL; Zhao, BX; Zhao, J | 1 |
| Albain, KS; Chansky, K; Crowley, J; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Vogel, SJ | 1 |
| Barbone, D; Broaddus, VC; Fennell, DA; Yang, TM | 1 |
| Carrell, JA; Humphreys, R; Luster, TA; McCormick, K; Sun, D | 1 |
| Ceresa, C; Giaccone, G; Giovannetti, E; Honeywell, R; Laan, AC; Peters, GJ; Voortman, J | 1 |
| Chen, L; Gao, M; Lei, N; Lu, Y; Wang, AY; Wu, JM; Xu, B; Zhang, CB; Zhang, LJ; Zhang, WW; Zheng, SZ | 1 |
| Camacho, FJ; Elrafei, T; Gucalp, R; Ho, L; Li, T; Perez-Soler, R; Piperdi, B; Rigas, JR | 1 |
| Powell, CA | 1 |
| Adachii, M; Ando, K; Hirose, T; Hosaka, T; Inoue, F; Ishida, H; Kadofuku, T; Kanome, T; Kusumoto, S; Ohmori, T; Ohnishi, T; Okuda, K; Saijo, N; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Bedor, M; Burrows, W; Edelman, MJ; Krasna, MJ; Smith, R; Suntharalingam, M | 1 |
| Albanell, J; Belda-Iniesta, C; Cejas, P; Chattopadhyay, S; Cortes-Sempere, M; de Castro-Carpeño, J; Gonzalez-Barón, M; Machado-Pinilla, R; Manguan-García, C; Moratilla, C; Nistal, M; Perona, R; Rodriguez-Fanjul, V; Rovira, A; Sánchez-Pérez, I; Tapia, M | 1 |
| Bodkin, D; Chiappori, A; Eton, O; Favis, R; Fenton, D; Halmos, B; Hirsh, V; Liu, H; Lynch, TJ; Middleman, EL; Shepherd, FA; Trepicchio, WL | 1 |
| Biesma, B; Bosquée, L; Chan, KC; De Marinis, F; Gans, S; Germonpré, P; Gervais, R; Lee, JS; Makhson, A; Manikhas, G; Morgan, B; Park, K; Planchard, D; Ramlau, R; Reck, M; Scagliotti, GV; Szczesna, A; Vansteenkiste, J; von Pawel, J; Zhu, Y | 1 |
| Gu, L; Kirshner, J; Lerro, K; Lilenbaum, R; Vokes, E; Wang, X | 1 |
| Amschler, K; Erpenbeck, L; Pletz, N; Schön, M; Schön, MP; Wallbrecht, K | 1 |
| Granberg, D; Hassan, S; Larsson, DE; Oberg, K; Wickström, M | 1 |
| Chen, Z; Ding, WB; Lou, YJ; Ye, ZQ; Yu, YP; Zhang, YD | 1 |
| Blackwell, TS; Kalomenidis, I; Karabela, SP; Kollintza, A; Magkouta, S; Moschos, C; Psallidas, I; Roussos, C; Sherrill, TP; Stathopoulos, GT; Theodoropoulou, P | 1 |
| Boozari, B; Gürlevik, E; Kloos, A; Knocke, S; Kubicka, S; Kühnel, F; Manns, MP; Mundt, B; Schache, P; Strüver, N; Wirth, TC; Woller, N | 1 |
| Cho, SH; Jones, DR; Lee, JK; Liu, Y; Nagji, AS | 1 |
| Argiris, A; Axelrod, RS; Burtness, B; Deconti, RC; Forastiere, AA; Ghebremichael, M | 1 |
| Bugaj, JE; Gokhale, PC; Guleryuz, S; Manning, HC; Mantis, C; McKinley, ET; Wild, R; Zhao, P | 1 |
| Argiris, A; Belani, CP; Gandara, DR; Gitlitz, B; Koczywas, M; Lara, PN; Lau, DH; Leighl, N; Longmate, J; Mack, PC; Ramalingam, S; Reckamp, K; Shepherd, FA; Wright, JJ | 1 |
| Dong, WL; Liu, N; Miao, JY; Su, L; Zhang, JH; Zhang, SL; Zhao, BX; Zhao, J | 1 |
| Miao, JY; Shao, JH; Zhao, BX; Zheng, LW | 1 |
| Belani, CP; Davies, AM; Edelman, MJ; Gandara, DR; Gitlitz, B; Lara, PN; Longmate, J; Ramalingam, SS; Reckamp, K; Salgia, R; Villalona-Calero, M; Vokes, EE; Wright, JJ | 1 |
| Bae, MS; Dong, MS; Gong, YD; Kang, NS; Kim, N; Lee, SB | 1 |
| Bronson, R; Feldser, DM; Jacks, T; Meylan, E; Oliver, TG; Winslow, MM; Xue, W | 1 |
| Assaraf, YG; Chan, ET; Cloos, J; de Wilt, LH; Jansen, G; Kirk, CJ; Kruyt, FA; Peters, GJ; Schimmer, AD; van Meerloo, J | 1 |
| Besse, B; Ducourtieux, M; Khayat, D; Lafontaine, C; Lumbroso, J; Mathiot, C; Pignon, JP; Planchard, D; Soria, JC; Taillade, L; Veillard, AS | 1 |
| Blackwell, TS; Cheng, DS; Gleaves, LA; Han, W; Kairi, CA; Kalomenidis, I; Karabela, SP; McMahon, F; Psallidas, I; Roussos, C; Sherrill, TP; Stathopoulos, GT; Stathopoulos, I; Vassiliou, S; Yull, FE; Zakynthinos, SG; Zaynagetdinov, R | 1 |
| Pan, XJ; Xiao, W; Yang, ZH; Zheng, CY; Zhou, SY; Zhu, MX | 1 |
| Hasegawa, S; Hashimoto, M; Lee-Kawabata, M; Masuyama, T; Naito, Y; Ogawa, H; Tamaki, H | 1 |
| Stockler, MR; Wilcken, NR | 1 |
| Cooley, K; Fergusson, D; Fernandes, R; Fritz, H; Kennedy, DA; Seely, D | 1 |
| Bathini, V; Bradley, K; Hanrahan-Boshes, M; Hutchinson, L; Perez-Soler, R; Piperdi, B; Walsh, WV; Zhou, Z | 1 |
| Gao, D; Guo, K; Jiang, K; Jin, G; Kang, X; Li, Y; Liu, Y; Shu, H; Sun, C; Sun, H; Sun, L; Wang, C; Wu, W | 1 |
| Balivada, S; Basel, MT; Bossmann, SH; Kalita, M; Moore, D; Pyle, M; Rachakatla, RS; Seo, GM; Shinogle, H; Shrestha, TB; Thapa, PS; Troyer, DL; Villanueva, D; Wang, H | 1 |
| Li, XW; Yang, JR | 1 |
| Liu, X; Su, L; Xu, L | 1 |
| Ishiyama, T; Jinguu, A; Kikuchi, J; Matsumoto, H; Suzuki, T; Yamakawa, M | 1 |
| Bao, Y; Burks, SG; Gillenwater, HH; Jones, DR; Kozower, BD; Moskaluk, CA; Olazagasti, J; Petroni, GR; Philips, J; Rehm, PK | 1 |
| Birdsell, CA; Crosby, NA; Ernstoff, MS; Poklepovic, A; Ramakrishnan, V; Roberts, JD; Winning, M; Youseffian, L; Youssefian, LE | 1 |
| Contreras, ML; Crowell, J; Dimitrov, NV; Madhukar, BV; Meyer-Leece, C | 1 |
| Pastorino, U; van Zandwijk, N | 1 |
| Adams, J; Elliott, PJ; Holland, JF; Jiang, JD; Liebes, L; Ling, YH; Muggia, FM; Perez-Soler, R | 1 |
| Liebes, L; Ling, YH; Perez-Soler, R; Zou, Y | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Mack, PC | 1 |
| Ikezoe, T; Kobayashi, M; Koeffler, HP; Saito, T; Taguchi, H; Yang, Y | 1 |
| Bold, RJ; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Mack, PC; Mortenson, MM | 1 |
| Broad, RM; Denlinger, CE; Jones, DR; Keller, MD; Mayo, MW | 1 |
| Bold, RJ; Mortenson, MM; Schlieman, MG; Virudachalam, S | 1 |
| Bunn, PA | 1 |
| Denlinger, CE; Jones, DR; Keller, MD; Rundall, BK | 1 |
| Denlinger, CE; Jones, DR; Rundall, BK | 1 |
| Reddy, KG | 1 |
| Belani, CP | 1 |
| Schenkein, DP | 2 |
| Dubey, S; Schiller, JH | 1 |
| Becker, F; Bergan, RC; Bhagat, R; Carmella, SG; Crowell, JA; Folz, RJ; Gallot, L; Glaser, EM; Hecht, SS; Herndon, JE; Kelley, MJ; Perloff, M; Santella, RM; Schilder, L; Zhang, YJ | 1 |
| Edelman, MJ | 2 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Matono, K; Mizobe, T; Nagase, H; Nakajima, M; Ogata, Y; Sasatomi, T; Shirouzu, K | 1 |
| Bold, RJ; Davies, AM; Gandara, DG; Lara, PN; Mortenson, MM; Schlieman, MG; Virudachalam, S | 1 |
| Alexandre, J | 1 |
| Feng, J; Sun, R; Tian, Z; Wei, H; Xiao, W; Xu, X; Zhen, C | 1 |
| Aggarwal, BB; Gutierrez, AM; Lotan, R; Shishodia, S | 1 |
| Adjei, AA | 1 |
| Bold, RJ; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Mack, PC | 2 |
| Govindan, R; Narra, V; Pillot, G; Subramanian, J | 1 |
| Scagliotti, G | 1 |
| Bonomi, P; Villaflor, V | 1 |
| Lilenbaum, R; Raez, LE | 1 |
| Gao, P; Sharma, S; Steele, VE | 1 |
| Giaccone, G; Voortman, J | 1 |
| Soria, JC | 1 |
| Auberger, J; Hilbe, W; Loeffler-Ragg, J; Wurzer, W | 1 |
| Avendaño, C; de la Cuesta, E; González, JF | 1 |
| Akerley, W; Axelrod, R; Belt, R; Carbone, DP; Crawford, J; Fanucchi, MP; Fidias, P; Fossella, FV; Govindan, R; Kashala, O; Kelly, K; Limentani, SA; Natale, R; Raez, LE; Reimers, HJ; Ribeiro, M; Robert, F; Schiller, JH; Sheng, S | 1 |
| Fenk, R; Garcia-Pardillos, G; Haas, R; Kronenwett, R; Meier, A; Neukirchen, J; Rohr, UP; Rohrbeck, A; Steidl, U | 1 |
| Checinska, A; Giaccone, G; Kruyt, FA; Rodriguez, JA; Voortman, J | 1 |
| Jung, CS; Khuri, FR; Sun, SY; Zhou, Z | 1 |
| Davies, AM; Doroshow, JH; Gandara, DR; Gumerlock, PH; Kashala, O; Koczywas, M; Lara, PN; Lau, DH; Lenz, HJ; Longmate, J; Quinn, DI; Schenkein, D | 1 |
| Atkins, JN; Chansky, K; Crowley, JJ; Davies, AM; Farneth, N; Franklin, WA; Gandara, DR; Guaglianone, PP; Gumerlock, PH; Lara, PN; Mack, PC | 1 |
| Chen, S; Hu, L; Khuri, FR; Liu, X; Lonial, S; Sun, SY; Yue, P | 1 |
| Giaccone, G; Honeywell, R; Kuenen, BC; Peters, GJ; Smit, EF; van de Velde, H; Voortman, J | 1 |
| Cadranel, JL; Garfield, DH | 1 |
| Abou El Hassan, MA; Giaccone, G; Kruyt, FA; Resende, TP; Voortman, J | 1 |
| Davies, AM; Gandara, DR; Lara, PN; Mack, PC | 1 |
| Ling, YH; Perez-Soler, R; Piperdi, B | 1 |
| Branch, CD; Chada, S; Gopalan, B; Ramesh, R; Scott, A; Shanker, M | 1 |
| Checińska, A; Giaccone, G; Voortman, J | 1 |
| Beckett, LA; Christensen, S; Davies, AM; Gandara, DR; Ho, C; Lara, PN; Lau, DH; Metzger, AS; Tanaka, M | 1 |
| Bold, R; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, DH; Lenz, HJ; Ruel, C; Schenkein, DP; Shibata, S | 1 |
| Brooks, AD; Elliott, PJ; Murphy, WJ; Sayers, TJ; Shanker, A; Smyth, MJ; Takeda, K; Tristan, CA; Wine, JW; Yagita, H | 1 |
| Katoh, I; Kyushiki, H; Sakamoto, Y; Yoshinaka, Y | 1 |
| Dent, G; Liebig, S; Magnussen, H; Rabe, KF; Schudt, C; Tenor, H | 1 |
| Kresty, LA; Morse, MA; Stoner, GD; Zu, H | 1 |
| Li, ZQ | 1 |
| Groopman, JD; Kensler, TW | 1 |
| Bagnasco, M; Bennicelli, C; Camoirano, A; De Flora, S; Kensler, TW; Qian, GS; van Zandwijk, N; Wigbout, G; Zhu, YR | 1 |
| Fujita, M; Higashino, K; Tsuchida, T | 1 |
| Chen, SX; Wang, LX; Xing, LL | 1 |
| Honma, Y; Kanatani, Y; Yamamoto-Yamaguchi, Y | 1 |
| Vandré, DD; Weitzel, DH | 1 |
| Bennett, JL; Bennink, M; Crowell, J; Dimitrov, NV; Gardiner, J; Hawk, E; Leece, CM; Nashawaty, M; Seymour, E; Tompkins, ER | 1 |
| Bai, H; Chen, F; Hu, G; Luo, X; Wei, H; Zhu, M | 1 |
| Balcerzak, SP; Galloway, S; Kraut, EH; Moore, T; Thomas, JP; Vandre, DD | 1 |
| Bouchard, L; Castonguay, A; Nicole, P; Pepin, P | 1 |
| Dykes, DJ; Griswold, DP; Harrison, SD; Plowman, J; Waud, WR | 1 |
| Bueding, E; Wattenberg, LW | 1 |
| Zorini, AO | 1 |
23 review(s) available for pyrazines and Lung Neoplasms
| Article | Year |
|---|---|
Single agent VS-6766 or VS-6766 plus defactinib in
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins p21(ras); Pyrazines; Sulfonamides | 2022 |
Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Imidazoles; Lung Neoplasms; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyridazines; Pyrimidines; Triazines | 2021 |
Savolitinib: First Approval.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; China; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Approval; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Pyrazines; Stomach Neoplasms; Triazines | 2021 |
Gilteritinib: First Global Approval.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Approval; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Lung Neoplasms; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic | 2019 |
Green tea and lung cancer: a systematic review.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA Damage; Herb-Drug Interactions; Humans; Lung Neoplasms; Maximum Tolerated Dose; Phytotherapy; Plant Extracts; Pyrazines; Tea | 2013 |
Chemoprevention of lung cancer: soon daily practice?
Topics: Acetylcysteine; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Antioxidants; Carotenoids; Clinical Trials as Topic; Diet; Humans; Lung Neoplasms; Pyrazines; Retinoids; Selenium; Smoking; Vitamin E | 2003 |
Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Ubiquitin | 2003 |
Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Humans; Lung Neoplasms; Peptide Hydrolases; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
The potential role of proteasome inhibitors in the treatment of lung cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines | 2004 |
Use of proteasome inhibition in the treatment of lung cancer.
Topics: Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2004 |
Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Glutamates; Guanine; Humans; Lung Neoplasms; Medical Oncology; Pemetrexed; Pyrazines | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
Preclinical data with bortezomib in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Interactions; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2005 |
Sequencing bortezomib with chemotherapy and targeted agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Drug Interactions; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2005 |
Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines | 2005 |
The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Radiation-Sensitizing Agents | 2005 |
Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Ubiquitin | 2005 |
Proteasome inhibitors in lung cancer.
Topics: Animals; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2006 |
Other compounds and targets in non-small cell lung cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Ligands; Lung Neoplasms; Membrane Glycoproteins; Proteasome Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
New developments in chemotherapy for advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epothilones; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Pyrazines | 2006 |
Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2006 |
Incorporating bortezomib into the treatment of lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lung Neoplasms; Pyrazines | 2007 |
Carcinogen-DNA and protein adducts: biomarkers for cohort selection and modifiable endpoints in chemoprevention trials.
Topics: Aflatoxin B1; Aflatoxins; Aged; Anticarcinogenic Agents; Biomarkers, Tumor; Carcinogens; Clinical Trials as Topic; Cohort Studies; DNA Adducts; Guanine; Hepatitis B; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Proteins; Pyrazines; Risk Factors; Thiones; Thiophenes | 1996 |
42 trial(s) available for pyrazines and Lung Neoplasms
| Article | Year |
|---|---|
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Focal Adhesion Protein-Tyrosine Kinases; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Proto-Oncogene Proteins p21(ras); Pyrazines; Salvage Therapy; Sulfonamides; Survival Rate | 2020 |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Salvage Therapy; Survival Rate; Triazines | 2020 |
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Topics: Acrylamides; Aniline Compounds; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazines; Triazines | 2020 |
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Triazines | 2021 |
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C.
Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Pyrazines; Triazines | 2021 |
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Topics: Carcinoma; Carcinoma, Non-Small-Cell Lung; Exons; Humans; Lung Neoplasms; Pyrazines; Triazines | 2021 |
Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Placebos; Platinum Compounds; Pyrazines; Receptors, Somatomedin | 2017 |
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines | 2018 |
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines | 2018 |
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Diarrhea; Double-Blind Method; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Nausea; Neurofibromin 2; Pleural Neoplasms; Pyrazines; Sulfonamides; Treatment Outcome | 2019 |
A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Survival Rate | 2019 |
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Pyrazines; Treatment Outcome; Vorinostat | 2014 |
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinazolines; Retrospective Studies; Sirolimus; Survival; Thiazoles; Treatment Outcome | 2013 |
A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pyrazines; Survival Analysis | 2015 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult | 2015 |
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Somatomedin; Young Adult | 2016 |
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Checkpoint Kinase 1; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome; Tumor Suppressor Protein p53 | 2016 |
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate | 2017 |
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate; Treatment Outcome | 2009 |
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Pyrazines | 2009 |
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Early Termination of Clinical Trials; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protease Inhibitors; Pyrazines; Treatment Failure; Tumor Burden; Venous Thrombosis | 2010 |
Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Early Termination of Clinical Trials; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Protease Inhibitors; Pyrazines; Radiotherapy; Respiratory Insufficiency | 2010 |
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Therapy, Combination; Dyspnea; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Pyrazines; Survival Analysis; Thrombocytopenia | 2010 |
Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Docetaxel; Female; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Taxoids | 2009 |
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Disease Progression; Doxorubicin; Female; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Recurrence; Survival Analysis | 2011 |
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pyrazines; Taxoids | 2011 |
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; California; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Survival Rate; Treatment Outcome | 2011 |
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Pyrazines; Survival Rate | 2012 |
Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Pyrazines; Survival Rate; Treatment Outcome; United States; Vascular Endothelial Growth Factor A | 2012 |
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Follow-Up Studies; Gene Expression Profiling; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Proteasome Endopeptidase Complex; Pyrazines; Vorinostat | 2012 |
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Melanoma; Middle Aged; Pyrazines; Radiography; Sarcoma; Treatment Outcome; Young Adult | 2013 |
Safety and efficacy of weekly oral oltipraz in chronic smokers.
Topics: 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; Administration, Oral; Adult; Aged; Anticarcinogenic Agents; Bronchoalveolar Lavage Fluid; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Polycyclic Aromatic Hydrocarbons; Pyrazines; Smoking; Thiones; Thiophenes | 2005 |
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Taxoids; Treatment Outcome; United States | 2006 |
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Probability; Pyrazines; Remission Induction; Risk Assessment; Survival Analysis | 2006 |
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines | 2007 |
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pemetrexed; Pyrazines; Survival Analysis | 2007 |
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Neutropenia; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome | 2008 |
[Effects of tetramethylpyrazine on platelet functions of advanced cases of lung carcinoma].
Topics: 6-Ketoprostaglandin F1 alpha; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazines; Thromboxane B2 | 1997 |
Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies.
Topics: Administration, Oral; Adult; Anticarcinogenic Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lipid Metabolism; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Probability; Pyrazines; Risk Assessment; Sensitivity and Specificity; Smoking; Statistics, Nonparametric; Thiones; Thiophenes; Tissue Distribution | 2001 |
A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Carcinoma, Small Cell; Female; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Pyrazines; Pyridines | 2002 |
134 other study(ies) available for pyrazines and Lung Neoplasms
| Article | Year |
|---|---|
Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
Topics: Animals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; DNA; Humans; Lung; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; TOR Serine-Threonine Kinases; Triazoles | 2022 |
Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib.
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Lymphoma, Mantle-Cell; Metformin; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2022 |
Case report: apatinib plus selexipag as a novel therapy for pulmonary tumor thrombotic microangiopathy accompanied by pulmonary hypertension associated with gastric carcinoma.
Topics: Acetamides; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Lung Neoplasms; Middle Aged; Pulmonary Artery; Pyrazines; Pyridines; Receptors, Epoprostenol; Receptors, Vascular Endothelial Growth Factor; Stomach Neoplasms; Thrombotic Microangiopathies | 2022 |
Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Triazines | 2022 |
Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Pyrazines; Pyrimidines; Triazines | 2022 |
Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Clustered Regularly Interspaced Short Palindromic Repeats; Gene Deletion; Histones; Humans; Lung Neoplasms; Mutation; Nitroso Compounds; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazines; Pyrimidines; RNA, Messenger; Sulfones; Tumor Suppressor Protein p53 | 2019 |
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Survival; Imidazoles; Lung Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Pyrazines; Pyridones; Pyrimidinones; Receptor, IGF Type 1; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Discovery; Drug Therapy, Combination; Female; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Structure; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
Topics: Acrylamides; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazines; Triazines | 2020 |
Non-Small Cell Lung Cancer Responds to Osimertinib plus Savolitinib.
Topics: Acrylamides; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazines; Triazines | 2020 |
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Topics: Acrylamides; Aged, 80 and over; Aniline Compounds; Animals; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 3-alpha; Humans; Imidazoles; Lung Neoplasms; Male; Mice; Models, Biological; Mutation; Phosphorylation; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; RNA, Messenger; Up-Regulation | 2020 |
Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Focal Adhesion Kinase 1; Gefitinib; Humans; Integrin alphaVbeta3; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Osteopontin; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Sulfonamides | 2020 |
Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation.
Topics: Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Small Cell Lung Carcinoma; Up-Regulation | 2021 |
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2021 |
MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity.
Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Cycle Proteins; Checkpoint Kinase 1; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mitosis; Multiprotein Complexes; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Signal Transduction; Trans-Activators | 2021 |
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Topics: Aged; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; DNA Replication; DNA Topoisomerases, Type I; Genomic Instability; Humans; Isoxazoles; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Small Cell Lung Carcinoma | 2021 |
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Epithelial Cells; Humans; Lung Neoplasms; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Polycomb Repressive Complex 1; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; RNA-Seq; Single-Cell Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Proliferation; Deoxycytidine; DNA Replication; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Isoxazoles; Lung Neoplasms; Mice; Mice, Nude; Morpholines; Pyrazines; Pyrazoles; Small Cell Lung Carcinoma; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Combination Treatment of OSI-906 with Aurora B Inhibitor Reduces Cell Viability via Cyclin B1 Degradation-Induced Mitotic Slippage.
Topics: Aurora Kinase B; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin B1; Dose-Response Relationship, Drug; Humans; Imidazoles; Lung Neoplasms; Mitosis; Protein Kinase Inhibitors; Proteolysis; Pyrazines; Quinazolines; Receptor, IGF Type 1 | 2021 |
Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatin; Chromatin Immunoprecipitation Sequencing; Chromosomal Proteins, Non-Histone; Cyclin-Dependent Kinase Inhibitor p57; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Glucocorticoids; Humans; Imidazoles; Immunohistochemistry; Lung Neoplasms; Mice; Proteomics; Pyrazines; Receptor, IGF Type 1; Receptors, Glucocorticoid; RNA-Seq; RNA, Small Interfering; Transcription Factors; Xenograft Model Antitumor Assays | 2021 |
ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Female; Heterografts; Humans; Isoxazoles; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Metastasis; Pyrazines; Treatment Outcome | 2021 |
Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Gastric Mucosa; Haplorhini; Humans; Lung; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Quinolines; Rats; Rats, Sprague-Dawley; Stomach; Stomach Neoplasms | 2017 |
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Checkpoint Kinase 1; Cisplatin; Drug Synergism; Female; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mice; Mice, Nude; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazines; Pyrazoles; Small Cell Lung Carcinoma | 2017 |
Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzodiazepinones; cdc25 Phosphatases; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Isoxazoles; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrazines; Pyrazoles; RNA, Messenger; Signal Transduction; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2017 |
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Topics: Animals; Benzamides; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Focal Adhesion Kinase 1; Focal Adhesion Kinase 2; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Transgenic; Neoplasms, Experimental; Pancreatic Neoplasms; Phosphorylation; Pleural Neoplasms; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinolones; Sulfonamides; Sulfones | 2018 |
Tetramethylpyrazine (TMPZ) triggers S-phase arrest and mitochondria-dependent apoptosis in lung cancer cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2018 |
Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
Topics: AC133 Antigen; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Gene Knock-In Techniques; Hepatocyte Growth Factor; Humans; Indicators and Reagents; Lung Neoplasms; Mice, Transgenic; Neoplastic Stem Cells; Phenotype; Pyrazines; Sulfonamides; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclodextrins; Humans; Lung Neoplasms; Mice, Nude; Pyrazines; Pyridines; Wnt Proteins; Wnt Signaling Pathway | 2018 |
Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesothelioma; Phenols; Pleural Neoplasms; Pyrazines; Quinolones; RNA Interference; Signal Transduction; Sulfonamides; Tumor Cells, Cultured; Verteporfin | 2018 |
A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.
Topics: Adenocarcinoma of Lung; Biopsy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; DNA Breaks, Double-Stranded; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Leukemic; Humans; Lung Neoplasms; MCF-7 Cells; Mutation; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Small Molecule Libraries; Triple Negative Breast Neoplasms | 2019 |
Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Survival; Checkpoint Kinase 1; Cisplatin; CRISPR-Associated Protein 9; DNA Damage; Drug Synergism; Etoposide; Humans; Isoxazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Small Cell Lung Carcinoma; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
Topics: Animals; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mutation; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Pyrrolidines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Highly bright and stable NIR-BRET with blue-shifted coelenterazine derivatives for deep-tissue imaging of molecular events
Topics: Amino Acid Sequence; Animals; Binding Sites; Breast Neoplasms; Chlorocebus aethiops; COS Cells; Female; Fluorescence Resonance Energy Transfer; HeLa Cells; Heterografts; Humans; Imidazoles; Liver Neoplasms; Luciferases; Luminescent Agents; Luminescent Measurements; Luminescent Proteins; Lung Neoplasms; Mice; Models, Molecular; Molecular Imaging; Protein Binding; Protein Interaction Domains and Motifs; Protein Structure, Secondary; Pyrazines; Receptors, Estrogen; Recombinant Fusion Proteins; Red Fluorescent Protein; Single-Cell Analysis | 2019 |
Mitochondrial dysfunction and therapeutic approaches in respiratory and limb muscles of cancer cachectic mice.
Topics: Acetylcysteine; Animals; Antioxidants; Boronic Acids; Bortezomib; Cachexia; Diaphragm; Electron Transport Chain Complex Proteins; Female; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mitochondria; Mitochondrial Diseases; Mitogen-Activated Protein Kinases; Muscle Strength; Muscle, Skeletal; NF-kappa B; Oxidative Stress; Pyrazines | 2013 |
Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Topics: Adenocarcinoma, Follicular; Adult; Boronic Acids; Bortezomib; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazines; Sorafenib; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Multidrug Resistance-Associated Proteins; Pemetrexed; Pyrazines; Selenious Acid | 2013 |
Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer.
Topics: Animals; Boronic Acids; Bortezomib; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; DNA Repair; Fanconi Anemia Complementation Group D2 Protein; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Rad51 Recombinase; Radiation-Sensitizing Agents; Radiation, Ionizing; Radiotherapy; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Xenograft Model Antitumor Assays | 2013 |
Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction | 2013 |
The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Microscopy, Electron, Scanning; Nanospheres; Pyrazines; Silicon Dioxide; Spectrophotometry, Ultraviolet | 2014 |
Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Depsipeptides; Drug Synergism; Histone Deacetylases; Histones; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrazines; Up-Regulation | 2014 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness.
Topics: Animals; Autophagy; Boronic Acids; Bortezomib; Butadienes; Cachexia; Cell Line, Tumor; Inflammation; Lung Neoplasms; Mice; Mice, Inbred BALB C; Muscle Contraction; Muscle Proteins; Muscle Weakness; Muscle, Skeletal; NF-kappa B; Nitriles; Oxidation-Reduction; Proteolysis; Pyrazines; Signal Transduction; Sulfasalazine; Tyrosine; Weight Gain | 2014 |
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Interactions; Drug Resistance, Multiple; HEK293 Cells; Humans; Imidazoles; Lung Neoplasms; Mitoxantrone; Models, Molecular; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Pyrazines | 2014 |
Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma.
Topics: Animals; Bombesin; Boronic Acids; Bortezomib; Cisplatin; GTP-Binding Protein alpha Subunits, G12-G13; GTP-Binding Protein alpha Subunits, Gq-G11; Hedgehog Proteins; HEK293 Cells; Humans; Lung Neoplasms; Mice; NIH 3T3 Cells; Oncogene Proteins; Pyrazines; Receptors, Bombesin; Signal Transduction; Small Cell Lung Carcinoma; Trans-Activators; Zinc Finger Protein GLI1 | 2015 |
The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
Topics: Antineoplastic Agents; Antirheumatic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Chloroquine; DNA Damage; DNA Repair; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; MAP Kinase Kinase 4; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Serine | 2014 |
Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Unfolded Protein Response | 2014 |
Pyrazine, 2-ethylpyridine, and 3-ethylpyridine are cigarette smoke components that alter the growth of normal and malignant human lung cells, and play a role in multidrug resistance development.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Lung; Lung Neoplasms; Nicotiana; Oxidative Stress; Pyrazines; Pyridines; Smoke | 2015 |
Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Depsipeptides; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; NF-kappa B; Pyrazines; Reactive Oxygen Species; Transcription, Genetic | 2015 |
Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Imidazoles; Lung Neoplasms; Mice; Models, Biological; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Protein Stability; Pyrazines; Receptor, IGF Type 1; Signal Transduction; src-Family Kinases | 2015 |
Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lung Neoplasms; Mice; Mutation; Pyrazines; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Topics: 4-Aminopyridine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclin-Dependent Kinases; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; HT29 Cells; Humans; Irinotecan; Lung Neoplasms; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Pyrazines; Xenograft Model Antitumor Assays | 2016 |
LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Colonic Neoplasms; Deoxycytidine; DNA Damage; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Xenograft Model Antitumor Assays | 2016 |
Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Curcumin; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Lung Neoplasms; Mice; Molecular Structure; Neoplasms, Experimental; Pyrazines; Reactive Oxygen Species; Structure-Activity Relationship; Thioredoxin-Disulfide Reductase | 2016 |
Tetramethylpyrazine inhibits tumor growth of lung cancer through disrupting angiogenesis via BMP/Smad/Id-1 signaling.
Topics: Angiogenesis Inhibitors; Animals; Bone Morphogenetic Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Differentiation Protein 1; Injections, Intraperitoneal; Lung Neoplasms; Mice; Pyrazines; Signal Transduction; Smad Proteins; Time Factors; Xenograft Model Antitumor Assays | 2016 |
Discovery of Novel (Imidazo[1,2-a]pyrazin-6-yl)ureas as Antiproliferative Agents Targeting P53 in Non-small Cell Lung Cancer Cell Lines.
Topics: Animals; Antineoplastic Agents; BALB 3T3 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Lung Neoplasms; Mice; Pyrazines; Tumor Suppressor Protein p53; Urea | 2016 |
Novel CHOP activator LGH00168 induces necroptosis in A549 human lung cancer cells via ROS-mediated ER stress and NF-κB inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Endoplasmic Reticulum Stress; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Necrosis; NF-kappa B; Pyrazines; Pyrimidines; Reactive Oxygen Species | 2016 |
IRE1α-TRAF2-ASK1 pathway is involved in CSTMP-induced apoptosis and ER stress in human non-small cell lung cancer A549 cells.
Topics: A549 Cells; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Survival; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Endoribonucleases; Humans; Lung Neoplasms; MAP Kinase Kinase Kinase 5; Mitochondria; Protein Binding; Protein Serine-Threonine Kinases; Pyrazines; RNA, Small Interfering; Signal Transduction; TNF Receptor-Associated Factor 2 | 2016 |
Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-myc; Pyrazines; TOR Serine-Threonine Kinases; Triazines | 2016 |
M867, a novel selective inhibitor of caspase-3 enhances cell death and extends tumor growth delay in irradiated lung cancer models.
Topics: Animals; Apoptosis; Autophagy; Base Sequence; Caspase Inhibitors; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Humans; Lung Neoplasms; Mice; Mice, Knockout; Oxadiazoles; Pyrazines; Radiation Tolerance; RNA, Small Interfering; Transplantation, Heterologous | 2008 |
The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Chromatography, High Pressure Liquid; Colony-Forming Units Assay; Drug Synergism; Drug Therapy, Combination; Humans; Immunoblotting; Immunoenzyme Techniques; In Situ Nick-End Labeling; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Mice, SCID; Multiple Myeloma; Oxidoreductases Acting on CH-NH Group Donors; Polyamine Oxidase; Polyamines; Pyrazines; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models.
Topics: Animals; Hydroxamic Acids; Lung Neoplasms; Male; Matrix Metalloproteinase Inhibitors; Melanoma, Experimental; Mice; Neoplasm Metastasis; Protease Inhibitors; Pyrazines; Sulfonamides | 2008 |
Pyrazino[1,2-b]isoquinolines: synthesis and study of their cytostatic and cytotoxic properties.
Topics: Adenocarcinoma; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Cytostatic Agents; DNA Damage; G1 Phase; G2 Phase; HT29 Cells; Humans; Inhibitory Concentration 50; Isoquinolines; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; S Phase; Structure-Activity Relationship | 2008 |
5-Alkyl-2-ferrocenyl-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives inhibit growth of lung cancer A549 cell by inducing apoptosis.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Ferrous Compounds; Humans; Integrin beta4; Lung Neoplasms; Molecular Structure; Pyrazines; Pyrazoles; Reactive Oxygen Species; RNA, Small Interfering; Structure-Activity Relationship | 2008 |
Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Communication; Cell Line, Tumor; Diffusion; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Nitrophenols; Phosphatidylinositol 3-Kinases; Piperazines; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recombinant Proteins; Signal Transduction; Spheroids, Cellular; Sulfonamides; Time Factors; TNF-Related Apoptosis-Inducing Ligand; TOR Serine-Threonine Kinases | 2009 |
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
Topics: Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Death; Cell Line, Tumor; Death Domain Receptor Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Humans; Lung Neoplasms; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2009 |
Ligustrazine inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by Vascular Endothelial Growth Factor.
Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Cell Proliferation; Female; Fibroblasts; Humans; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Pyrazines; Rats; Vascular Endothelial Growth Factor A | 2009 |
Rounding up apoptosis resistance targets in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Communication; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recombinant Proteins; Signal Transduction; Spheroids, Cellular; TNF-Related Apoptosis-Inducing Ligand | 2009 |
Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Pyrazines; Quinazolines; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2009 |
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chromones; Cisplatin; Dual Specificity Phosphatase 1; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Morpholines; NF-kappa B; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; RNA Interference; Signal Transduction; Sulfones | 2009 |
NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Lung Neoplasms; Melanoma; Mice; NF-kappa B; Oxazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyridines; Skin Neoplasms | 2010 |
The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro.
Topics: Apoptosis; Benzophenanthridines; Boronic Acids; Bortezomib; Brefeldin A; Carcinoid Tumor; Carcinoma, Bronchogenic; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Lung Neoplasms; Naphthoquinones; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrazines | 2010 |
[4, 8-disubstituted-8, 9-dihydro-pyrazine[2,3-g]quinazoline-7(6H)-ketones: a novel class of antitumor agents].
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; K562 Cells; Lung Neoplasms; Molecular Structure; Pyrazines; Quinazolines; Stomach Neoplasms; Structure-Activity Relationship | 2010 |
Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Inflammation; Inflammation Mediators; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Neovascularization, Pathologic; NF-kappa B; Pleural Effusion, Malignant; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2010 |
Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Combined Modality Therapy; Endoplasmic Reticulum; Female; Immunity, Cellular; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Oncolytic Virotherapy; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Tumor Cells, Cultured; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2010 |
Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.
Topics: Algorithms; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Gene Expression Profiling; Humans; Hydroxamic Acids; Lung Neoplasms; Multigene Family; Pyrazines; Vorinostat | 2010 |
18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Drug Evaluation, Preclinical; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Receptor, Insulin; Xenograft Model Antitumor Assays | 2011 |
Microwave-assisted synthesis, crystal structure of pyrazolo[1,5-a]pyrazin-4(5H)-ones and their selective effects on lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Microwaves; Models, Molecular; Molecular Structure; Pyrazines; Pyrazoles; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |
Synthesis of novel pyrazolo[1,5-a]pyrazin-4(5H)-one derivatives and their inhibition against growth of A549 and H322 lung cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; Humans; Inhibitory Concentration 50; Lung Neoplasms; Magnetic Resonance Spectroscopy; Molecular Structure; Pyrazines | 2011 |
A novel 3-arylethynyl-substituted pyrido[2,3,-b]pyrazine derivatives and pharmacophore model as Wnt2/β-catenin pathway inhibitors in non-small-cell lung cancer cell lines.
Topics: Antineoplastic Agents; beta Catenin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Models, Molecular; Molecular Structure; Pyrazines; Pyridines; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured; Wnt Proteins | 2011 |
Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Lung Neoplasms; Mice; Mice, 129 Strain; NF-kappa B; Nitriles; Pyrazines; Signal Transduction; Sulfones; Survival Rate; Transcription Factor RelA | 2011 |
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
Topics: Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Proteasome Endopeptidase Complex; Protein Binding; Pyrazines | 2012 |
Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; NF-kappa B; Pyrazines | 2012 |
Inhibition of cyclooxygenase-2 by tetramethylpyrazine and its effects on A549 cell invasion and metastasis.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Humans; Immunoglobulin G; Lung Neoplasms; Matrix Metalloproteinase 2; Melphalan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pyrazines; Xenograft Model Antitumor Assays | 2012 |
Curative resection of double primary lung cancer after 15-month bortezomib administration.
Topics: Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Pneumonectomy; Pyrazines; Treatment Outcome | 2012 |
Why is management of cancer pain still a problem?
Topics: Analgesics; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Colorectal Neoplasms; Female; Healthcare Disparities; Humans; Lung Neoplasms; Male; Multiple Myeloma; Pain Management; Practice Patterns, Physicians'; Prostatic Neoplasms; Pyrazines | 2012 |
Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Proto-Oncogene Proteins c-akt; Pyrazines; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
Stem cell-based photodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Cell Survival; Female; Fetal Blood; Imidazoles; Luciferases; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Neural Stem Cells; Oxidation-Reduction; Photochemotherapy; Photosensitizing Agents; Plasmids; Protoporphyrins; Pyrazines; Rats; Stem Cell Transplantation; Stem Cells; Transfection | 2012 |
[Effects of secoisolariciresinol diglucoside combined with bortezomib on induction of apoptosis in lung cancer cell line A549].
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Butylene Glycols; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Therapy, Combination; Flow Cytometry; Glucosides; Humans; Lung Neoplasms; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Real-Time Polymerase Chain Reaction; RNA, Messenger | 2012 |
PKCδ regulates death receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis in human lung cancer cells.
Topics: Activating Transcription Factor 3; Activating Transcription Factor 4; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Endoplasmic Reticulum Stress; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gene Silencing; Humans; Lung Neoplasms; Phosphorylation; Protein Binding; Protein Kinase C-delta; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Ribosomal Protein S6 Kinases, 90-kDa; Time Factors; Transcription Factor CHOP; Up-Regulation | 2012 |
[A case of adult primitive neuroectodermal tumor(PNET)with multiple lung metastases effectively treated with ADM, IFM(AI)regimen].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Boronic Acids; Bortezomib; Doxorubicin; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melphalan; Middle Aged; Mitolactol; Mitomycins; Neuroectodermal Tumors, Primitive; Pyrazines; Salvage Therapy; Suicide; Tomography, X-Ray Computed | 2012 |
Inhibition of mitogen-activated protein kinase activity of human lymphocytes after oral administration of Oltipraz.
Topics: Administration, Oral; Adult; Anticarcinogenic Agents; Blotting, Western; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Lymphocytes; Male; MAP Kinase Signaling System; Middle Aged; Phosphorylation; Pyrazines; Signal Transduction; Thiones; Thiophenes | 2002 |
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Dose-Response Relationship, Drug; G2 Phase; Humans; Immunohistochemistry; Lung Neoplasms; Microtubules; Mitosis; Multienzyme Complexes; Mutation; Precipitin Tests; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2003 |
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Antineoplastic Agents; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Survival; Cysteine Endopeptidases; Cytochrome c Group; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Immunoblotting; Indicators and Reagents; Lung Neoplasms; Membrane Potentials; Mitochondria; Models, Chemical; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Reactive Oxygen Species; Time Factors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme-Linked Immunosorbent Assay; Genes, jun; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Transcription Factor AP-1; Tumor Suppressor Protein p53 | 2004 |
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Butyrates; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Cysteine Endopeptidases; Histone Deacetylases; Humans; Interleukin-8; Lung Neoplasms; Multienzyme Complexes; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Transcription, Genetic; Transcriptional Activation; Treatment Outcome; Tumor Cells, Cultured | 2004 |
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2004 |
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Proteins; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factor RelA; Transcription, Genetic; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2004 |
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Mitochondria; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Transcription, Genetic; Vorinostat | 2004 |
Activity of bortezomib in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
Emerging advances in the management of lung cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Paclitaxel; Polyglutamic Acid; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
Lung cancer - Second Annual Winter Conference.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines | 2005 |
Efficacy of the MMP inhibitor MMI270 against lung metastasis following removal of orthotopically transplanted human colon cancer in rat.
Topics: Administration, Oral; Animals; Apoptosis; Chemoprevention; Colonic Neoplasms; Humans; Hydroxamic Acids; Lung Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Pyrazines; Rats; Rats, Nude; Sulfonamides; Survival Analysis; Transplantation, Heterologous | 2006 |
Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Gene Expression Regulation, Neoplastic; Humans; Luciferases; Lung Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 2005 |
[Proteasome inhibitors].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Drug Therapy, Combination; Female; Graft vs Host Reaction; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Type two cytokines predominance of human lung cancer and its reverse by traditional Chinese medicine TTMP.
Topics: Adult; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cytokines; Drugs, Chinese Herbal; Female; Gene Expression; Humans; Ligusticum; Lung Neoplasms; Male; Medicine, Chinese Traditional; Mice; Middle Aged; Pyrazines | 2004 |
N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Carrier Proteins; Cell Growth Processes; Cyclin D1; Cyclooxygenase 2; Down-Regulation; Drug Synergism; Enzyme Activation; Fenretinide; Genes, myc; Humans; I-kappa B Kinase; I-kappa B Proteins; Lung Neoplasms; Membrane Glycoproteins; NF-kappa B; NF-KappaB Inhibitor alpha; Oncogene Protein v-akt; Osteoclasts; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2005 |
Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC). A case report.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lung Neoplasms; Male; Pyrazines; Tomography, X-Ray Computed | 2006 |
The chemopreventive efficacy of inhaled oltipraz particulates in the B[a]P-induced A/J mouse lung adenoma model.
Topics: Adenoma; Animals; Anticarcinogenic Agents; Benzo(a)pyrene; Female; Inhalation; Lung Neoplasms; Mice; Mice, Inbred A; Pyrazines; Thiones; Thiophenes | 2006 |
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Comorbidity; Deoxycytidine; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Risk Factors; Ventricular Dysfunction, Left | 2006 |
[Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic; Research; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A | 2006 |
Synthesis and cytotoxic activity of pyrazino[1,2-b]-isoquinolines, 1-(3-isoquinolyl)isoquinolines, and 6,15-iminoisoquino[3,2-b]-3-benzazocines.
Topics: Azocines; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Lung Neoplasms; Molecular Conformation; Pyrazines; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2007 |
The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Genes, p53; Genetic Therapy; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Transfection; Tumor Cells, Cultured | 2007 |
Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Caspases; Cisplatin; Cytochromes c; Humans; Lung Neoplasms; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Cells, Cultured; Up-Regulation | 2007 |
Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Survivin; Taxoids; Tumor Cells, Cultured | 2007 |
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; Survivin; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2007 |
Possible mechanism(s) of action of bortezomib in a patient with bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lung Neoplasms; Male; Models, Biological; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53 | 2007 |
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Models, Biological; NF-kappa B; Proteasome Inhibitors; Pyrazines; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Drug Interactions; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Tumor Cells, Cultured | 2007 |
MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
Topics: Adenoviridae; Boronic Acids; Bortezomib; Catalytic Domain; Cell Line, Tumor; Female; Genetic Therapy; Humans; Interleukins; Lung Neoplasms; Lysosomes; Ovarian Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Tumor Suppressor Proteins; Ubiquitin; Ubiquitination | 2008 |
The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; Cell Line, Tumor; Humans; Lung Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Sensitivity and Specificity | 2007 |
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Humans; Immunoblotting; Kidney Neoplasms; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mitochondrial Membranes; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2008 |
Alterations of the cytoskeletal organization in tumor cell lines by a cardiotonic drug, vesnarinone, through protein tyrosine phosphorylation.
Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Carcinoma, Squamous Cell; Cardiotonic Agents; Catechols; Cell Communication; Cell Line; Cell Line, Transformed; Cytoskeleton; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Genes, src; Humans; Immunoblotting; Lung Neoplasms; Mice; Nitriles; Phosphoproteins; Phosphotyrosine; Protein-Tyrosine Kinases; Pyrazines; Quinolines; Tubulin; Tumor Cells, Cultured; Tyrosine; Tyrphostins; Vimentin | 1995 |
Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization.
Topics: 1-Methyl-3-isobutylxanthine; 2',3'-Cyclic-Nucleotide Phosphodiesterases; Adult; Aged; Bucladesine; Colforsin; Dibutyryl Cyclic GMP; Dose-Response Relationship, Drug; Female; Forced Expiratory Volume; Humans; In Vitro Techniques; Isoenzymes; Lung; Lung Neoplasms; Male; Middle Aged; Muscle Relaxation; Muscle Tonus; Muscle, Smooth; Nitroprusside; Purinones; Pyrazines; Pyridazines; Pyrrolidinones; Rolipram; Vital Capacity | 1993 |
Failure of dietary oltipraz to inhibit benzo[a]pyrene-induced lung tumorigenesis in strain a mice.
Topics: Adenoma; Animals; Anticarcinogenic Agents; Benzopyrenes; Diet; Female; Glutathione Transferase; Lung; Lung Neoplasms; Mice; Mice, Inbred A; Pyrazines; Thiones; Thiophenes | 1995 |
[Study on initiation of human lung carcinogenesis].
Topics: Anticarcinogenic Agents; Cell Transformation, Neoplastic; Cells, Cultured; Diethylnitrosamine; Humans; Lung Neoplasms; Pyrazines; Smoking; Thiones; Thiophenes | 1993 |
Smokers and urinary genotoxins: implications for selection of cohorts and modulation of endpoints in chemoprevention trials.
Topics: Acetylcysteine; Adult; Anticarcinogenic Agents; Biomarkers, Tumor; Chemoprevention; China; Clinical Trials, Phase II as Topic; Cohort Studies; DNA Repair; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenicity Tests; Mutagens; Netherlands; Pyrazines; Research Design; Smoking; Thiones; Thiophenes | 1996 |
Effect of vesnarinone in combination with anti-cancer drugs on lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Division; Cisplatin; Coloring Agents; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Pyrazines; Quinolines; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1999 |
Vesnarinone and glucocorticoids cooperatively induce G1 arrest and have an anti-tumour effect on human non-small cell lung carcinoma cells grown in nude mice.
Topics: Alkaline Phosphatase; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Division; Dexamethasone; Drug Synergism; G1 Phase; Glucocorticoids; Humans; Lung Neoplasms; Mice; Neoplasm Transplantation; Pyrazines; Quinolines; Retinoblastoma Protein; Tumor Cells, Cultured | 1999 |
Differential spindle assembly checkpoint response in human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Carbamates; Fluorescent Antibody Technique, Indirect; Giant Cells; Humans; Lung Neoplasms; Microtubules; Mitosis; Pyrazines; Pyridines; Spindle Apparatus; Tumor Cells, Cultured | 2000 |
[Studies on apoptosis of human lung adenocarcinoma cells induced by oltipraz].
Topics: Adenocarcinoma; Anticarcinogenic Agents; Apoptosis; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Mitosis; Pyrazines; Thiones; Thiophenes; Tumor Cells, Cultured | 1999 |
Effects of sulindac and oltipraz on the tumorigenicity of 4-(methylnitrosamino)1-(3-pyridyl)-1-butanone in A/J mouse lung.
Topics: Adenoma; Animals; Carcinogens; Drug Screening Assays, Antitumor; Female; Intestinal Absorption; Lung; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Nitrosamines; Oxidation-Reduction; Pyrazines; Schistosomicides; Sulindac; Thiones; Thiophenes | 1992 |
Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.
Topics: Animals; Antineoplastic Agents; Drug Administration Schedule; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Leukemia L1210; Leukemia P388; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Pyrazines | 1990 |
Inhibitory effects of 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (Oltipraz) on carcinogenesis induced by benzo[a]pyrene, diethylnitrosamine and uracil mustard.
Topics: Animals; Benzo(a)pyrene; Diethylnitrosamine; Female; Lung Neoplasms; Mice; Mice, Inbred ICR; Neoplasms, Experimental; Pyrazines; Stomach Neoplasms; Thiones; Thiophenes; Uracil Mustard | 1986 |
Chest diseases in Italy.
Topics: Antitubercular Agents; Bronchitis; Cycloserine; Humans; Italy; Lung Diseases; Lung Neoplasms; Pyrazines; Rifampin; Tuberculosis; Tuberculosis, Pulmonary | 1966 |